23.00
3.69%
-0.88
Dopo l'orario di chiusura:
23.80
0.80
+3.48%
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
Zacks Investment Research
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
GlobeNewswire Inc.
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
GlobeNewswire Inc.
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
Zacks Investment Research
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Seeking Alpha
2 Stocks Down 30% to Buy Right Now
The Motley Fool
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
The Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
The Motley Fool
Better Cathie Wood Stock: Moderna vs. Intellia
The Motley Fool
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
Zacks Investment Research
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
GlobeNewswire Inc.
Is Intellia Therapeutics Stock a Buy Now?
The Motley Fool
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
The Motley Fool
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
The Motley Fool
Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors
Zacks Investment Research
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The Motley Fool
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average
Zacks Investment Research
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
Benzinga
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update
Zacks Investment Research
Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High?
Zacks Investment Research
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
Zacks Investment Research
Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
The Motley Fool
Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?
Zacks Investment Research
Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?
The Motley Fool
C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?
Zacks Investment Research
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Zacks Investment Research
Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?
Zacks Investment Research
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
GlobeNewswire Inc.
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
Zacks Investment Research
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
Zacks Investment Research
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
GlobeNewswire Inc.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
Zacks Investment Research
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The Motley Fool
Not Shy Of Buying The Dip, Cathie Wood's Ark Mops Up Over $11M Worth Of Shares In Tesla — Sells Nvidia Stock
Benzinga
A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist
The Motley Fool
Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?
Zacks Investment Research
Cathie Wood's Ark Invest Snatches Up $4.7M More In Tesla Shares, Invests Equally In This Rocket Company
Benzinga
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
GlobeNewswire Inc.
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.
The Motley Fool
Down -19.06% in 4 Weeks, Here's Why Intellia Therapeutics, Inc. (NTLA) Looks Ripe for a Turnaround
Zacks Investment Research
2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street
The Motley Fool
Is It Too Late to Buy Intellia Therapeutics Stock?
The Motley Fool
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
The Motley Fool
Is it a Good Idea to Invest in Intellia (NTLA) Stock Now?
Zacks Investment Research
Dow Jones Extends Historic Streak: Are More All-Time Highs in the Cards?
Investing.com
The Top Healthcare Stocks to Buy With $100
The Motley Fool
Is Intellia Therapeutics (NTLA) Stock a Solid Choice Right Now?
Zacks Investment Research
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
The Motley Fool
Capitalizzazione:
|
Volume (24 ore):